Posted: 24 Jan 2013 03:34 PM PST
Ampligen, the first drug ever seeking approval to treat chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME), recently hit another roadblock with the U.S. Food and Drug Administration (FDA).
In its long quest to treat 1 million Americans suffering from this debilitating illness, the FDA advisory panel did not recommend the drug to be sold on the market, largely because CFS/ME doesn't have clear biomarkers such as blood tests to define patients who most likely to respond to the drug.
A leading clinician argues that the real loser is not Ampligen, but CFS/ME patients whose daily suffering continues to be unabated.
No comments:
Post a Comment